Latest Neisseria Stories
With today's approval, Bexsero is now licensed in 37 countries; since first approval in Europe, over 1 million doses have been distributed worldwide BASEL, Switzerland, Jan.
Submission follows receipt of Breakthrough Therapy designation in April 2014, highlighting unmet need for a licensed vaccine for serogroup B in the US(1) BASEL, Switzerland, June 17, 2014 /PRNewswire/
Transparency Market Research published a new report "Meningococcal Vaccines Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.
DUBLIN, May 19, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/rd8s6p/meningococcal)
Olympic Medalist swimmer and mother, Dara Torres, and the National Association of School Nurses launch multi-city health initiative as part of Voices of Meningitis(TM) SILVER SPRING, Md.
ALBANY, New York, May 9, 2014 /PRNewswire/ -- According to a new report published by Transparency Market Research "Meningococcal Vaccines Market (Polysaccharide, Conjugate,
Researchers have come a step closer to understanding how gonorrhea infections are transmitted.
DORVAL QC, Feb.
- FDA granted special use of Bexsero for nearly 20,000 UCSB students and staff in response to outbreak; the vaccine is licensed in Europe, Australia and Canada CAMBRIDGE, Mass., Feb.
Neisseria meningitidis is a heterotrophic gram-negative diplococcal bacterium best known for its role in meningitis and other forms of meningococcal disease such as meningococcemia. It is a major cause of morbidity and mortality during childhood in industrialized countries and is responsible for epidemics in Africa and in Asia. In the US there are approximately 2500 to 3500 cases of N. meningitides infections. Children under 5 are at a higher risk as well as people in the sub-Saharan...